VIDEO: 2/28/2023 (February 24, 2023) | By Ross Youngs. Ross Youngs’ Presentation to George Mason University/VA The Most Powerful Small Molecule Drug Discovery Platform Industrial Scale Microbiome Mining
MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders-Seventure etc (February 17, 2023) | By Maat Pharma SA. MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders Lyon, France, February 17, 2023, 7:30 am CET – MaaT Pharma (EURONEXT: MAAT –
PODCAST: 2/16/2023 (February 16, 2023) | By David Levine. The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy. The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and
Merck hands Swedish biotech €10M cash to develop anti-inflammatory drugs (February 16, 2023) | By Katherine Lewin, News Reporter. Merck is betting on Aqilion’s work on a small molecule inhibitor for autoimmune and inflammatory diseases, including neurological diseases. Merck is paying €10 million upfront cash to the Swedish-based biotech in a licensing deal and research collaboration
By Ross Youngs, February 2, 2023. 12 QUESTIONS to ChatGPT MICROBIOME DISCOVERY Chat GPT from OpenAI is a new and interesting way of interrogating the universe of data online and formulating it into a cohesive human communication format. To prove the point that this will be part of the next generations of human efficiency improvement that
